January 23, 2024 07:24 AM ESTUpdated 10:33 AM

J&J meets Q4 expectations with $21.4B in sales as it stares down patent cliff

Katherine Lewin

News Reporter

Johnson & Johnson met its forecasts for the fourth quarter of 2023, reporting a 7.3% sales growth to $21.4 billion and full-year reported sales increase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J meets Q4 expectations with $21.4B in sales as it stares down patent cliff

Katherine Lewin

News Reporter

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Applied Therapeutics' rare disease drug gets a CRL

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

J&J meets Q4 ex­pec­ta­tions with $21.4B in sales as it stares down patent cliff

Katherine Lewin

News Reporter

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

J&J meets Q4 expectations with $21.4B in sales as it stares down patent cliff

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Applied Therapeutics' rare disease drug gets a CRL

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam